Chronic Hepatitis C of 28 Years' Duration Characterized by Early Development of Stage 2 (of 4) Fibrosis but No Significant Progression over the Subsequent 18 Years

Elizabeth C Verna; Jay H Lefkowitch; Paul D Berk

doi:10.1055/s-0030-1262516

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2010; 30(3): 302-309
DOI: 10.1055/s-0030-1262516

DIAGNOSTIC PROBLEMS IN HEPATOLOGY

Chronic Hepatitis C of 28 Years' Duration Characterized by Early Development of Stage 2 (of 4) Fibrosis but No Significant Progression over the Subsequent 18 Years

Elizabeth C. Verna¹ , Jay H. Lefkowitch² , Paul D. Berk¹

¹Department of Medicine, Division of Digestive and Liver Diseases, Columbia University College of Physicians and Surgeons, New York, New York
²Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York

Abstract

Full Text

References

REFERENCES

1 Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991; 13(3) 372-374
2 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. Am J Med. 1952; 13(5) 567-569
3 Cuttner J. Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura. JAMA. 1974; 227(4) 397-402
4 Amorosi E L, Karpatkin S. Antiplatelet treatment of thrombotic thrombocytopenic purpura. Ann Intern Med. 1977; 86(1) 102-106
5 Amorosi E, Ultmann J. Thrombotic, thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966; 45 139-159
6 Cuttner J. Thrombotic thrombocytopenic purpura: a ten-year experience. Blood. 1980; 56(2) 302-306
7 Liang T J, Rehermann B, Seeff L B, Hoofnagle J H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4) 296-305
8 Sangiovanni A, Prati G M, Fasani P et al.. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006; 43(6) 1303-1310
9 Seeff L B, Buskell-Bales Z, Wright E C et al.. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992; 327(27) 1906-1911
10 Seeff L B, Hollinger F B, Alter H J et al.. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001; 33(2) 455-463
11 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995; 332(22) 1463-1466
12 Kiyosawa K, Sodeyama T, Tanaka E et al.. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990; 12(4 Pt 1) 671-675
13 Datz C, Cramp M, Haas T et al.. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999; 44(4) 563-567
14 Barrett S, Goh J, Coughlan B et al.. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001; 49(3) 423-430
15 Seeff L B, Miller R N, Rabkin C S et al.. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000; 132(2) 105-111
16 Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology. 2000; 32(1) 91-96
17 Rodger A J, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology. 2000; 32(3) 582-587
18 de Lédinghen V, Trimoulet P, Mannant P R et al.. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol. 2007; 46(1) 19-25
19 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055) 825-832
20 Zarski J P, Mc Hutchison J, Bronowicki J P et al.. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003; 38(3) 307-314
21 Hand D. Statistics and theory of measurements. J R Stat Soc. 1996; 159 445-492
22 Berk P D. An editor's look-back. Hepatology. 2006; 43(2, Suppl 1) S13-S30
23 The French METAVIR Cooperative Study Group . Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994; 20(1 Pt 1) 15-20
24 Westin J, Lagging L M, Wejstål R, Norkrans G, Dhillon A P. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 1999; 19(3) 183-187
25 Goldin R D, Goldin J G, Burt A D et al.. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996; 25(5) 649-654
26 Hourigan L F, Macdonald G A, Purdie D et al.. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999; 29(4) 1215-1219
27 Clouston A D, Jonsson J R, Purdie D M et al.. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol. 2001; 34(2) 314-320
28 Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33(6) 1358-1364
29 Everhart J E, Lok A S, Kim H Y HALT-C Trial Group et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009; 137(2) 549-557
30 Kallwitz E R, Layden-Almer J, Dhamija M et al.. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol. 2010; 8(1) 72-78
31 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112(2) 463-472
32 Gordon S C, Bayati N, Silverman A L. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998; 28(2) 562-567
33 Bonis P A, Tong M J, Blatt L M, Conrad A, Griffith J L. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol. 1999; 94(6) 1605-1612
34 Yano M, Kumada H, Kage M et al.. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23(6) 1334-1340
35 Marcellin P, Boyer N, Gervais A et al.. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997; 127(10) 875-881
36 Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 1999; 30(5) 783-787
37 Formann E, Steindl-Munda P, Hofer H et al.. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther. 2006; 23(4) 507-511
38 Shiratori Y, Imazeki F, Moriyama M et al.. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000; 132(7) 517-524
39 Veldt B J, Heathcote E J, Wedemeyer H et al.. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147(10) 677-684
40 Maylin S, Martinot-Peignoux M, Moucari R et al.. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135(3) 821-829
41 George S L, Bacon B R, Brunt E M, Mihindukulasuriya K L, Hoffmann J, Di Bisceglie A M. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49(3) 729-738
42 Imai Y, Kawata S, Tamura S Osaka Hepatocellular Carcinoma Prevention Study Group et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998; 129(2) 94-99
43 Kasahara A, Hayashi N, Mochizuki K Osaka Liver Disease Study Group et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998; 27(5) 1394-1402
44 International Interferon-alpha Hepatocellular Carcinoma Study Group . Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998; 351(9115) 1535-1539
45 Okanoue T, Itoh Y, Minami M Viral Hepatitis Therapy Study Group et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999; 30(4) 653-659
46 Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001; 34(4) 593-602
47 Di Bisceglie A M, Shiffman M L, Everson G T HALT-C Trial Investigators et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359(23) 2429-2441
48 Sulkowski M S, Mehta S H, Torbenson M S et al.. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007; 21(16) 2209-2216
49 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33(4) 562-569
50 Fong T L, Valinluck B, Govindarajan S, Charboneau F, Adkins R H, Redeker A G. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 1994; 107(1) 196-199
51 Henry S D, Metselaar H J, Van Dijck J, Tilanus H W, Van Der Laan L J. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci. 2007; 1110 439-447
52 Magrin S, Craxi A, Fabiano C et al.. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994; 19(2) 273-279
53 Calleja J L, Albillos A, Cacho G, Iborra J, Abreu L, Escartín P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol. 1996; 24(3) 308-312
54 Bahra M, Neumann U P, Jacob D, Langrehr J M, Neuhaus P. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc. 2005; 37(4) 1700-1702
55 Berenguer M, Aguilera V, Prieto M et al.. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006; 44(4) 717-722
56 Berenguer M, Ferrell L, Watson J et al.. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32(4) 673-684
57 Neumann U P, Berg T, Bahra M et al.. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004; 77(2) 226-231

Paul D BerkM.D.

Professor of Medicine, Columbia University Medical Center, Division of Digestive and Liver Diseases, William Black Medical Research Building

Room 1002, 650 West 168th Street, New York, NY 10032

Email: pb2158@columbia.edu